Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 937 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 Running a cancer helpline in COVID-19: two years on the virtual... March 23, 2022 Summer Sun Safety Tips September 3, 2020 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 Load more HOT NEWS Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... Survivorship and Immune Checkpoint Inhibitors
